A Phase 2 Study of Nivolumab + BMS-986016 (Relatlimab) in Patients With Metastatic Uveal Melanoma
Latest Information Update: 09 Dec 2024
Price :
$35 *
At a glance
- Drugs Nivolumab (Primary) ; Relatlimab (Primary)
- Indications Uveal melanoma
- Focus Therapeutic Use
- Sponsors Bristol-Myers Squibb
- 05 Dec 2024 Planned End Date changed from 1 Dec 2026 to 4 Jan 2026.
- 29 Nov 2023 Planned End Date changed from 1 Dec 2025 to 1 Dec 2026.
- 29 Nov 2023 Planned primary completion date changed from 1 Dec 2023 to 1 Dec 2024.